Last reviewed · How we verify
NCT06598982
Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis
trial in Systemic Sclerosis (SSc) in 85 participants. Currently enrolling.
2 January 2025
Quick facts
| Lead sponsor | Selcuk University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 85 |
| Start date | 1 July 2024 |
| Primary completion | 2 January 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Systemic Sclerosis (SSc) — all drugs for Systemic Sclerosis (SSc) →
- Scleroderma — all drugs for Scleroderma →
Sponsor
Selcuk University
Who can join
Adults 18 to 75, any sex, with Systemic Sclerosis (SSc) or Scleroderma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to investigate respiratory muscle sarcopenia in individuals with systemic sclerosis. The main question it aims to answer is: What is the prevalence of respiratory muscle sarcopenia in patients with systemic sclerosis? Participants body composition (bioelectrical impedance), hand grip strength (hand dynanometer), physical performance tests (5 repetition sit-and-stand test, 4-meter walk test, Timed up-and-go test) and respiratory muscle strength were evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06598982
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Sclerosis (SSc)
Currently open trials in the same condition.
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07413341 — A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases · Phase 1 · recruiting
- NCT07360808 — Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis · NA · recruiting
- NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting
Other Selcuk University trials
Trials by the same sponsor.
- NCT07402499 — Validation of a Virtual Reality Timed Up and Go Test in Adults With Chronic Non-Specific Low Back Pain · not yet recruiting
- NCT07364591 — Immediate Effect of Kinesiotaping With Rounded Shoulder Posture in University Students · NA · not yet recruiting
- NCT07381244 — Validity, Reliability, and Clinical Correlates of Immersive Virtual Reality Adaptation of the Five Times Sit-to-stand Te · not yet recruiting
- NCT07373704 — Respiratory Muscle Strength and Endurance Cut-Offs in Multiple Sclerosis · not yet recruiting
- NCT07362368 — Virtual Reality-Based Five-Repetition Sit-to-Stand Test in Young Adults · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06598982 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Selcuk University
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06598982.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing